Fimognari Filippo Luca, Violi Francesco
Division of Internal Medicine, ASL Roma G, Leopoldo Parodi-Delfino Hospital, Colleferro, Rome, Italy.
Intern Emerg Med. 2008 Sep;3(3):213-8. doi: 10.1007/s11739-008-0128-0. Epub 2008 Feb 15.
Portal vein thrombosis (PVT) is observed in 10-20% of patients with liver cirrhosis, which is responsible for 20% of all PVT cases. The main pathogenic factor of PVT in cirrhosis is the obstacle to portal flow, but acquired and inherited clotting abnormalities may play a role. The formation of collateral veins allows many patients to remain asymptomatic and prevents the onset of clinical complications also in patients with totally occlusive PVT. Gastrointestinal bleeding, thrombosis of superior mesenteric vein and refractory ascites are typical manifestations of PVT. Instrumental diagnosis can be obtained by colour-doppler ultrasonography. Future studies should verify whether asymptomatic PVT worsens liver failure, or if its life-threatening complications reduce survival in patients with cirrhosis. Moreover, randomized controlled trials should clarify the potential effectiveness of anticoagulant therapy in the treatment of PVT.
门静脉血栓形成(PVT)在10%-20%的肝硬化患者中可见,占所有PVT病例的20%。肝硬化患者发生PVT的主要致病因素是门静脉血流受阻,但获得性和遗传性凝血异常可能也起作用。侧支静脉的形成使许多患者保持无症状,并且在完全闭塞性PVT患者中也可预防临床并发症的发生。胃肠道出血、肠系膜上静脉血栓形成和难治性腹水是PVT的典型表现。彩色多普勒超声检查可进行器械诊断。未来的研究应验证无症状PVT是否会加重肝衰竭,或者其危及生命的并发症是否会降低肝硬化患者的生存率。此外,随机对照试验应阐明抗凝治疗在PVT治疗中的潜在有效性。